Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Phase 2

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Biological: Belantamab Mafodotin
Drug: Lenalidomide

First Posted Date: 2021-05-06

Last Posted Date: 2024-11-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04876248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Early Phase 1

Withdrawn

Conditions: Malignant Solid Neoplasm
Pancreatic Carcinoma
Colorectal Carcinoma
Lung Adenocarcinoma

Interventions: Drug: Binimetinib
Drug: Palbociclib
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-05-03

Last Posted Date: 2023-12-22

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04870034

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Phase 1

Suspended

Conditions: Lung Non-Small Cell Carcinoma
Pleural Disorder

Interventions: Drug: Porfimer Sodium
Procedure: Video-Assisted Thoracic Surgery
Drug: Photodynamic Therapy
Device: Intraoperative PDT

First Posted Date: 2021-04-08

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04836429

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study

Early Phase 1

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Thermotherapy

First Posted Date: 2021-03-18

Last Posted Date: 2022-05-12

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04803630

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SurVaxM Expanded Access Protocol

Conditions: Glioblastoma

First Posted Date: 2021-03-17

Last Posted Date: 2025-06-04

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT04802447

Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors

Not Applicable

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Survey Administration
Other: Yoga

First Posted Date: 2021-02-15

Last Posted Date: 2025-06-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 27

Registration Number: NCT04754529

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effects of Filter Ventilation and Ventilation Information on Product Use Behaviors in Cigarette Smokers

Not Applicable

Completed

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Other: Cigarette packaging
Other: Data capture
Other: Questionnaire administration

First Posted Date: 2021-02-08

Last Posted Date: 2023-12-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 115

Registration Number: NCT04744285

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Biological: Atezolizumab
Drug: Carboplatin
Drug: Etoposide
Drug: Lamivudine

First Posted Date: 2021-01-06

Last Posted Date: 2025-05-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 28

Registration Number: NCT04696575

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Esophageal Adenocarcinoma

Interventions: Drug: Carboplatin
Radiation: 3 Dimensional Conformal Radiation Therapy
Drug: Propranolol
Radiation: Intensity Modulated Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2020-12-23

Last Posted Date: 2025-04-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 106

Registration Number: NCT04682158

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy

Not Applicable

Recruiting

Conditions: Prostate Carcinoma

Interventions: Procedure: Electroencephalography
Procedure: Electromyography
Other: Questionnaire Administration
Procedure: Urodynamics (UDS)

First Posted Date: 2020-11-30

Last Posted Date: 2024-08-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 100

Registration Number: NCT04646434

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy